Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 24 of 114

  1. CA239-0004

    Bristol-Myers Squibb Australia Pty Ltd

    Locally Advanced or Metastatic Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  2. CA240-0029

    Bristol-Myers Squibb Australia Pty Ltd

    metastatic non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  3. CA240-0030

    Bristol-Myers Squibb Australia Pty Ltd

    Untreated Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  4. CA244-0008

    Bristol-Myers Squibb Australia Pty Ltd

    Breast cancer, Triple-negative breast cancer

    phase 3 small molecule active

    1 trial

  5. CA244-0010

    Bristol-Myers Squibb Australia Pty Ltd

    EGFR-mutated Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  6. CA2440012

    Bristol-Myers Squibb Australia Pty Ltd

    Metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  7. CA245-0001

    Bristol-Myers Squibb Australia Pty Ltd

    Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  8. CA2660001

    Bristol-Myers Squibb Australia Pty Ltd

    Unresectable Stage III non-small cell lung cancer without progression

    phase 3 small molecule active

    1 trial

  9. CA2660002

    Bristol-Myers Squibb Australia Pty Ltd

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  10. CA2660003

    Bristol-Myers Squibb Australia Pty Ltd

    Untreated, Unresectable or Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  11. CA2660004

    Bristol-Myers Squibb Australia Pty Ltd

    Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  12. CA41705

    Hoffmann-La Roche

    Lupus Nephritis (LN)

    phase 3 small molecule active

    1 trial

  13. CA42750

    Hoffmann-La Roche

    Systemic Lupus Erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  14. CAAA601A22301

    Advanced Accelerator Applications

    Patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs

    phase 3 small molecule active

    1 trial

  15. CAAA601A62301

    Novartis Pharmaceuticals

    Gastroenteropancreatic neuroendocrine tumor (GEP-NET)

    phase 3 small molecule active

    1 trial

  16. CAAA617B12302

    Novartis Pharmaceuticals

    PSMA-positive metastatic castration-resistant prostate cancer

    phase 3 small molecule active

    1 trial

  17. CAAA617C12301

    Novartis Pharmaceuticals

    PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)

    phase 3 small molecule active

    1 trial

  18. CAAA617D12302

    Novartis Pharmaceuticals

    Oligometastatic prostate cancer (OMPC)

    phase 3 small molecule active

    1 trial

  19. CABAZITAXEL

    Sanofi Pasteur

    Prostate Cancer Metastatic

    phase 3 small molecule completed

    1 trial

  20. CABL001A2001B

    Novartis Pharmaceuticals

    chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

    phase 3 small molecule active

    1 trial

  21. CABL001J12301

    Novartis Pharmaceuticals

    Chronic Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  22. CABL001J12302

    Novartis Pharmaceuticals

    Chronic Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  23. CADET-PAD

    COLLEGIUM PHARMACEUTICAL, INC

    Ischemia of the lower limbs in the course of obstructive artery disease

    phase 3 small molecule active

    1 trial

  24. CAIN457H1301

    Novartis Pharmaceuticals

    Ankylosing Spondylitis

    phase 3 small molecule completed

    1 trial

  25. CAIN457M2301E1

    Novartis Pharmaceuticals

    Hidradenitis suppurativa

    phase 3 small molecule active

    1 trial

  26. CAIN457R12301

    Novartis Pharmaceuticals

    Giant cell arteritis (GCA)

    phase 3 small molecule active

    1 trial

  27. CAIN457R1DE01

    Novartis Pharmaceuticals

    Giant Cell Arteritis

    phase 3 small molecule active

    1 trial

  28. CAMER5UA

    United Therapeutics Europe Ltd

    Cervical Artery Dissection

    phase 3 small molecule completed

    1 trial

  29. CANAKINUMAB, PEMETREXED

    Novartis Pharmaceuticals

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  30. CAPECITABINE

    Disc Medicine

    Salivary Duct Carcinoma

    phase 3 small molecule active

    1 trial

  31. CAPECITABINE for Locally advanced stage II/III rectal cancer

    Fondazione Telethon ETS

    Locally advanced stage II/III rectal cancer

    phase 3 small molecule active

    1 trial

  32. CARDIOL 100-03

    Cardiol Therapeutics

    COVID-19

    phase 3 small molecule terminated

    1 trial

  33. CAZ-AVI

    Pfizer

    Complicated Intra-Abdominal Infection

    phase 3 small molecule completed

    1 trial

  34. CB8025-31731-RE

    Gilead Sciences Pty Limited

    Primary Biliary Cholangitis

    phase 3 other active

    1 trial

  35. CBAF312D2301

    Novartis Pharmaceuticals

    Multiple Sclerosis in pediatric patients

    phase 3 small molecule active

    1 trial

  36. CBD 100 mg/mL Oral Solution

    COGNITION THERAPEUTICS INC

    Treatment Resistant Psychosis

    phase 3 small molecule active

    1 trial

  37. CBD 100 mg/mL Oral Solution

    COGNITION THERAPEUTICS INC

    Psychosis

    phase 3 small molecule active

    1 trial

  38. CBP-201

    S.L

    Atopic Dermatitis

    phase 3 small molecule active

    2 trials

  39. CBYL719C2303

    Novartis Pharmaceuticals

    Hormone receptor positive, HER2-negative advanced breast cancer

    phase 3 small molecule active

    1 trial

  40. CBYL719K12301

    Novartis Pharmaceuticals

    Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation

    phase 3 small molecule active

    1 trial

  41. CBYL719P12201

    Novartis Pharmaceuticals

    lymphatic malformations associated with PIK3CA mutation

    phase 3 small molecule active

    1 trial

  42. CC-220-MM-002

    Celgene Europe Limited

    Relapsed or Refractory Multiple Myeloma (RRMM)

    phase 3 small molecule active

    1 trial

  43. CCM 1862

    Cardiol Therapeutics

    congestive heart failure

    phase 3 small molecule active

    1 trial

  44. CCTL019A2205B

    Novartis Pharmaceuticals

    All patients who have been treated with Novartis or Penn CAR T-cell therapy for any indication

    phase 3 small molecule active

    1 trial

  45. CCTL019H2301

    Novartis Pharmaceuticals

    Adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

    phase 3 small molecule active

    1 trial

  46. CD101.IV.3.08

    Mundipharma Pty Limited

    Invasive Fungal Diseases in Adults undergoing Allogeneic Blood and Marrow Transplantation (BMT)

    phase 3 small molecule active

    1 trial

  47. CDZ173/Leniolisib, CDZ173/Leniolisib

    Pharming Technologies B.V.

    Activated Phosphoinositide 3-Kinase Delta Syndrome

    phase 3 small molecule active

    1 trial

  48. CEP-10953 (Armodafinil)

    Teva Pharma GmbH

    Narcolepsy

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.